Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Short Interest Down 51.7% in February

Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) was the recipient of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 73,200 shares, a decrease of 51.7% from the January 31st total of 151,400 shares. Based on an average trading volume of 126,100 shares, the short-interest ratio is presently 0.6 days.

Tevogen Bio Stock Performance

Shares of NASDAQ TVGNW traded down $0.00 during mid-day trading on Friday, reaching $0.07. The company’s stock had a trading volume of 53,708 shares, compared to its average volume of 162,857. The stock has a fifty day moving average of $0.07 and a two-hundred day moving average of $0.05. Tevogen Bio has a 52 week low of $0.01 and a 52 week high of $0.15.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.